--- title: "Vivos Therapeutics (VVOS) news: convertible notes" url: "https://aibio.space/companies/vivos-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "VVOS convertible notes news: Vivos Therapeutics issues convertible note of up to $5,000,000. Vivos Therapeutics, Inc. (NASDAQ: VVOS), United States." --- VVOS Vivos Therapeutics, Inc. NASDAQ · United States # Vivos Therapeutics (VVOS) news VVOS convertible notes news Debt Financing · 2026-06-08 ## [Vivos Therapeutics issues convertible note of up to $5,000,000](https://aibio.space/news/vivos-therapeutics-issues-convertible-note-up-5-000-000/) Vivos Therapeutics can draw up to $5,000,000 under a note from V-CO Investors 4 LLC, which adds a 10% bridge fee to each amount advanced and converts into the equity of a planned financing. The lender may call the note on demand once the June 30, 2026 Outside Date has passed. ## Latest Vivos Therapeutics news We have not published a story on Vivos Therapeutics yet. When there is news, it will appear here. ## Vivos Therapeutics at a glance - **Ticker**: VVOS - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $1.8 million ### Related companies - [LivaNova](https://aibio.space/companies/livanova/) NASDAQ: LIVN - [WEED, INC.](https://aibio.space/companies/weed/) OTC: BUDZ - [FOXO TECHNOLOGIES INC.](https://aibio.space/companies/foxo-technologies/) OTC: FOXO - [GLOBUS MEDICAL INC](https://aibio.space/companies/globus-medical/) NYSE: GMED - [YD Bio](https://aibio.space/companies/yd-bio/) NASDAQ: YDES - [TFA Therapeutics](https://aibio.space/companies/tfa-therapeutics/) OTC: RAJAF - [EBR Systems](https://aibio.space/companies/ebr-systems/) OTC: EBRCZ - [Leef Brands](https://aibio.space/companies/leef-brands/) OTC: LEEEF ### Also on NASDAQ - [Bicycle Therapeutics](https://aibio.space/companies/bicycle-therapeutics/) BCYC - [Palatin Technologies](https://aibio.space/companies/palatin-technologies/) PTN - [Verrica Pharmaceuticals](https://aibio.space/companies/verrica-pharmaceuticals/) VRCA - [Polyrizon](https://aibio.space/companies/polyrizon/) PLRZ - [Nkarta](https://aibio.space/companies/nkarta/) NKTX - [InspireMD](https://aibio.space/companies/inspiremd/) NSPR ## Vivos Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$17.4 million](https://www.sec.gov/Archives/edgar/data/1716166/000149315226016854/) | [$15.0 million](https://www.sec.gov/Archives/edgar/data/1716166/000149315226016854/) | | Research and development | [$100,000](https://www.sec.gov/Archives/edgar/data/1716166/000149315226016854/) | [$100,000](https://www.sec.gov/Archives/edgar/data/1716166/000149315226016854/) | | Net income (loss) | [-$21.2 million](https://www.sec.gov/Archives/edgar/data/1716166/000149315226016854/) | [-$11.1 million](https://www.sec.gov/Archives/edgar/data/1716166/000149315226016854/) | | Cash from operations | [-$15.3 million](https://www.sec.gov/Archives/edgar/data/1716166/000149315226016854/) | [-$12.7 million](https://www.sec.gov/Archives/edgar/data/1716166/000149315226016854/) | | Cash and equivalents | [$2.0 million](https://www.sec.gov/Archives/edgar/data/1716166/000149315226038336/) | [$6.3 million](https://www.sec.gov/Archives/edgar/data/1716166/000149315226016854/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $1.8 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Vivos Therapeutics Has Vivos Therapeutics sold convertible notes? Our latest story on this, dated Jun 8, 2026: "Vivos Therapeutics issues convertible note of up to $5,000,000". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/vivos-therapeutics-issues-convertible-note-up-5-000-000/). What is the ticker symbol of Vivos Therapeutics? Vivos Therapeutics, Inc. trades under the ticker VVOS on NASDAQ. Where is Vivos Therapeutics listed? Vivos Therapeutics, Inc. is listed on NASDAQ. Which country or territory is Vivos Therapeutics listed under? Our directory records Vivos Therapeutics, Inc. under United States. Does aibio.space cover Vivos Therapeutics? aibio.space lists Vivos Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. What was Vivos Therapeutics's revenue last year? $17.4 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Vivos Therapeutics profitable? Vivos Therapeutics, Inc. reported a net loss of $21.2 million for the fiscal year ended Dec 31, 2025, and used $15.3 million of cash in operations, per its annual report to the SEC. How much does Vivos Therapeutics spend on research and development? $100,000 in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Vivos Therapeutics have? $1.8 million in cash at Jun 30, 2026, per its 10-Q. What is the latest Vivos Therapeutics (VVOS) stock news? Our latest story on Vivos Therapeutics, dated Jun 8, 2026: "Vivos Therapeutics issues convertible note of up to $5,000,000". Vivos Therapeutics can draw up to $5,000,000 under a note from V-CO Investors 4 LLC, which adds a 10% bridge fee to each amount advanced and converts into the equity of a planned financing. The lender may call the note on demand once the June 30, 2026 Outside Date has passed. [Source](https://aibio.space/news/vivos-therapeutics-issues-convertible-note-up-5-000-000/). How can I follow Vivos Therapeutics (VVOS) news? Press Follow on this page to add Vivos Therapeutics to your Following list, or subscribe to the aibio.space newsletter. We have published 1 story naming Vivos Therapeutics so far, in Debt Financing. ## Investor discussion: Vivos Therapeutics Members talk about Vivos Therapeutics (VVOS). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Vivos Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-10-29 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1716166/000149315226049258/formdef14a.htm) 2. 2026-10-21 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1716166/000149315226047841/ex99-1.htm) 3. 2026-10-19 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,3.02,3.03,5.03,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1716166/000149315226047601/ex99-1.htm) 4. 2026-10-19 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1716166/000149315226047606/formpre14a.htm) 5. 2026-10-15 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1716166/000149315226047158/ex99-1.htm) 6. 2026-10-01 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1716166/000149315226045193/form8-k.htm) 7. 2026-07-07 Listings Reported a reverse stock split. SEC Form 8-K (Items 1.01,3.02,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1716166/000149315226032387/form8-k.htm) 8. 2026-06-25 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1716166/000149315226030190/ex99-1.htm) 9. 2026-06-08 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,2.03,3.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1716166/000149315226027641/ex99-1.htm) 10. 2026-05-15 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1716166/000149315226023733/formnt10-q.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:VVOS on TradingView](https://www.tradingview.com/symbols/NASDAQ-VVOS/). ## Listing details Vivos Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker VVOS, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Vivos Therapeutics, Inc. - **Ticker**: VVOS - **Listing**: NASDAQ - **Country or territory**: United States Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/vivos-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Vivos Therapeutics (VVOS) news: convertible notes", 2026-10-31, https://aibio.space/companies/vivos-therapeutics/